PURPOSE: We determined the prognostic significance of lymphovascular invasion (LVI) in patients treated for invasive transitional cell carcinoma of the bladder with radical cystectomy. MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer with intent to cure. All patients with nontransitional cell carcinoma histology, palliative procedures, unknown lymphovascular status, less than pT1 pathological stage, or any neoadjuvant or adjuvant chemotherapy/radiation therapy were excluded, leaving 702 comprising the study cohort. Of the 702 patients 249 (36%) had LVI. RESULTS: Median followup was 11.0 years (range 8 days to 23.2 years). Overall 5 and 10-year survival was 51% and 34%, while 5 and 10-year recurrence-free survival was 66% and 64%, respectively. Ten-year recurrence-free survival in patients without LVI was 74% compared with 42% in those with LVI (p <0.0001). Similarly 10-year overall survival was 43% in patients without LVI compared with 18% in those with LVI (p <0.0001). In the organ confined/lymph node negative and lymph node positive pathological subgroups survival outcomes were significantly worse if LVI was present. Although a trend was observed, LVI status was not statistically significant in patients with extravesical node negative disease. Stepwise Cox regression analysis revealed that pathological subgroup (organ confined, extravesical and lymph node positive) (p <0.0001) and LVI status (p = 0.0004) were independent prognostic variables for recurrence-free and overall survival. CONCLUSIONS: Lymphovascular invasion appears to be an important and independent prognostic variable in patients with invasive bladder cancer treated with radical cystectomy. LVI status should be determined in cystectomy specimens, which may provide further risk stratification in patients following radical cystectomy.
PURPOSE: We determined the prognostic significance of lymphovascular invasion (LVI) in patients treated for invasive transitional cell carcinoma of the bladder with radical cystectomy. MATERIALS AND METHODS: From August 1971 to June 2004, 2,005 patients underwent radical cystectomy for primary bladder cancer with intent to cure. All patients with nontransitional cell carcinoma histology, palliative procedures, unknown lymphovascular status, less than pT1 pathological stage, or any neoadjuvant or adjuvant chemotherapy/radiation therapy were excluded, leaving 702 comprising the study cohort. Of the 702 patients 249 (36%) had LVI. RESULTS: Median followup was 11.0 years (range 8 days to 23.2 years). Overall 5 and 10-year survival was 51% and 34%, while 5 and 10-year recurrence-free survival was 66% and 64%, respectively. Ten-year recurrence-free survival in patients without LVI was 74% compared with 42% in those with LVI (p <0.0001). Similarly 10-year overall survival was 43% in patients without LVI compared with 18% in those with LVI (p <0.0001). In the organ confined/lymph node negative and lymph node positive pathological subgroups survival outcomes were significantly worse if LVI was present. Although a trend was observed, LVI status was not statistically significant in patients with extravesical node negative disease. Stepwise Cox regression analysis revealed that pathological subgroup (organ confined, extravesical and lymph node positive) (p <0.0001) and LVI status (p = 0.0004) were independent prognostic variables for recurrence-free and overall survival. CONCLUSIONS: Lymphovascular invasion appears to be an important and independent prognostic variable in patients with invasive bladder cancer treated with radical cystectomy. LVI status should be determined in cystectomy specimens, which may provide further risk stratification in patients following radical cystectomy.
Authors: Vladimir Novotny; Michael Froehner; Matthias May; Chris Protzel; Katrin Hergenröther; Michael Rink; Felix K Chun; Margit Fisch; Florian Roghmann; Rein-Jüri Palisaar; Joachim Noldus; Michael Gierth; Hans-Martin Fritsche; Maximilian Burger; Danijel Sikic; Bastian Keck; Bernd Wullich; Philipp Nuhn; Alexander Buchner; Christian G Stief; Stefan Vallo; Georg Bartsch; Axel Haferkamp; Patrick J Bastian; Oliver W Hakenberg; Stefan Propping; Atiqullah Aziz Journal: World J Urol Date: 2015-02-08 Impact factor: 4.226
Authors: R Lyle Hood; William F Carswell; Amanda Rodgers; Mehmet A Kosoglu; Marissa Nichole Rylander; David Grant; John L Robertson; Christopher G Rylander Journal: Lasers Med Sci Date: 2012-10-04 Impact factor: 3.161
Authors: Ertuğrul Şefik; Serdar Çelik; Bülent Günlüsoy; İsmail Basmacı; Serkan Yarımoğlu; İbrahim Halil Bozkurt; Tansu Değirmenci; Çetin Dinçel Journal: Turk J Urol Date: 2019-04-03
Authors: Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Adam Conley; David E Durrant; Anindita Das; Paul B Fisher; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent Journal: Mol Pharmacol Date: 2013-12-18 Impact factor: 4.436
Authors: Eiji Kikuchi; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Shuji Mikami; Yair Lotan; Mesut Remzi; Christian Bolenz; Cord Langner; Alon Weizer; Francesco Montorsi; Karim Bensalah; Theresa M Koppie; Mario I Fernández; Jay D Raman; Wassim Kassouf; Christopher G Wood; Nazareno Suardi; Mototsugu Oya; Shahrokh F Shariat Journal: J Clin Oncol Date: 2008-12-15 Impact factor: 44.544
Authors: E Hernando; J Sarmentero-Estrada; T Koppie; C Belda-Iniesta; V Ramírez de Molina; P Cejas; C Ozu; C Le; J J Sánchez; M González-Barón; J Koutcher; C Cordón-Cardó; B H Bochner; J C Lacal; A Ramírez de Molina Journal: Oncogene Date: 2009-05-18 Impact factor: 9.867